NXGL: Q2 revenue reached $3.69M with a $2.87M net loss; integration and expansion efforts continue
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue was $3.69M with a net loss of $2.87M, impacted by non-recurring items and a strategic recall. Integration of acquisitions and expansion into hospital and regenerative medicine markets are underway, with supply chain and shareholder approval challenges persisting.Original document: NexGel, Inc [NXGL] SEC 8-K Current Report — Aug. 25 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue was $3.69M with a net loss of $2.87M, impacted by non-recurring items and a strategic recall. Integration of acquisitions and expansion into hospital and regenerative medicine markets are underway, with supply chain and shareholder approval challenges persisting.
Original document: NexGel, Inc [NXGL] SEC 8-K Current Report — Aug. 25 2026